{"id":"NCT01577537","sponsor":"Starpharma Pty Ltd","briefTitle":"A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","officialTitle":"A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04-17","primaryCompletion":"2012-10-05","completion":"2012-10-05","firstPosted":"2012-04-16","resultsPosted":"2019-07-09","lastUpdate":"2019-07-17"},"enrollment":251,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Vaginosis"],"interventions":[{"type":"DRUG","name":"1% SPL7013 Gel","otherNames":["VivaGel"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"VivaGel","type":"EXPERIMENTAL"},{"label":"HEC Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV).\n\nAfter screening eligible participants will be randomized to receive either 1% SPL7013 Gel or hydroxyethyl cellulose (HEC) placebo gel at a dose of 5g administered vaginally at bedtime for 7 consecutive days. Participants will be assessed for BV (both by Amsel criteria and Nugent score) at screening/Baseline, after last application (End of Treatment, EOT, Day 9-12) and at the final study visit approximately 2-3 weeks after last dose (Test of Cure, TOC, Day 21-30).","primaryOutcome":{"measure":"Number of Women With Clinical Cure at the End of Treatment Visit (EOT)","timeFrame":"Day 9-12","effectByArm":[{"arm":"VivaGel","deltaMin":68,"sd":null},{"arm":"HEC Placebo","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":126},"commonTop":[]}}